Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
- Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. Currently, more than 500 CAR-T and 17 CAR-NK cell trials are being conducted worldwide including the four CAR-T cell products Kymriah, Yescarta, Tecartus and Breyanzi, which are already available on the market. Most CAR-T cell-based gene therapy products that are under clinical evaluation consist of autologous enriched T cells, whereas CAR-NK cell-based approaches can be generated from allogeneic donors. Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany.
Verfasserangaben: | Nawid AlbingerORCiD, Jessica HartmannORCiDGND, Evelyn UllrichORCiDGND |
---|---|
URN: | urn:nbn:de:hebis:30:3-750786 |
DOI: | https://doi.org/10.1038/s41434-021-00246-w |
ISSN: | 1476-5462 |
Titel des übergeordneten Werkes (Englisch): | Gene therapy |
Verlag: | Nature Publ. Group |
Verlagsort: | London |
Dokumentart: | Wissenschaftlicher Artikel |
Sprache: | Englisch |
Datum der Veröffentlichung (online): | 22.03.2021 |
Datum der Erstveröffentlichung: | 22.03.2021 |
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Datum der Freischaltung: | 13.10.2023 |
Freies Schlagwort / Tag: | Cancer; Immunotherapy |
Jahrgang: | 28 |
Ausgabe / Heft: | 9 |
Seitenzahl: | 15 |
Erste Seite: | 513 |
Letzte Seite: | 527 |
Bemerkung: | The laboratory of EU has been supported by the FCI and DKTK (to EU), by the DFG (CRC/SFB 1292 and IRTG; to EU and NA), by the German Cancer Aid (to EU), the “Alfred & Angelika Gutermuth-Stiftung” (to EU), and by “Menschen für Kinder e.V.” (to EU). Open Access funding enabled and organized by Projekt DEAL. |
HeBIS-PPN: | 515003387 |
Institute: | Medizin |
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Lizenz (Deutsch): | Creative Commons - CC BY - Namensnennung 4.0 International |